Compass Therapeutics Inc

+0.12 (+2.65%)
Earnings Announcements

Compass Therapeutics Reports Q3 Financial Results, Provides Corporate Update

Published: 11/09/2022 14:47 GMT
Compass Therapeutics Inc (CMPX) - Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update.compass Therapeutics- Initiated Preclinical Toxicology Studies for Ctx-8371; Ind Filing & First in Human Clinical Study Are Anticipated in H1 of 2023.
Qtrly Loss per Share $0.12.
Q3 Earnings per Share View $-0.11 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.11

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.12

More details on our Analysts Page.